Back to Search
Start Over
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response
- Source :
- Hepatology, Hepatology, Wiley-Blackwell, 2010, 52 (4), pp.1201-7. ⟨10.1002/hep.23816⟩
- Publication Year :
- 2010
-
Abstract
- International audience; UNLABELLED: The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatment-naïve patients from 133 centers were treated with PEG-IFN alfa-2b (1.5 μg/kg/week) plus RBV (800-1,400 mg/day). Patients with detectable hepatitis C virus (HCV) RNA and a ≥2-log(10) drop in HCV RNA levels at week 12 (slow responders) were randomized 1:1 to receive 48 weeks (n = 86) or 72 weeks (n = 73) of treatment. Sustained virologic response (SVR) rates were 43% in slow responders treated for 48 weeks and 48% in slow responders treated for 72 weeks (P = 0.644). Relapse rates were similar in slow responders treated for 48 or 72 weeks (47% versus 33%, P = 0.169). The safety profile was similar in both treatment arms; serious adverse events leading to discontinuation of treatment were observed in 3.5% of slow responders treated for 48 weeks and 8.2% of those treated for 72 weeks. Among slow responders with a
- Subjects :
- Male
Time Factors
Medizin
Hepacivirus
medicine.disease_cause
Gastroenterology
law.invention
Polyethylene Glycols
MESH: Recombinant Proteins
chemistry.chemical_compound
0302 clinical medicine
Randomized controlled trial
law
INFECTION
Medicine
MESH: Hepacivirus
MESH: Treatment Outcome
MESH: Aged
MESH: Middle Aged
Hepatitis C
Middle Aged
Viral Load
PLUS RIBAVIRIN
Recombinant Proteins
3. Good health
MESH: Hepatitis C, Chronic
Treatment Outcome
030220 oncology & carcinogenesis
MESH: RNA, Viral
Peginterferon alfa-2b
RNA, Viral
030211 gastroenterology & hepatology
Drug Therapy, Combination
Female
MESH: Interferon-alpha
MESH: Viral Load
Viral load
medicine.drug
MESH: Antiviral Agents
Adult
medicine.medical_specialty
Adolescent
Hepatitis C virus
Interferon alpha-2
Antiviral Agents
Drug Administration Schedule
03 medical and health sciences
MESH: Ribavirin
Internal medicine
Ribavirin
Humans
Aged
MESH: Adolescent
MESH: Humans
Hepatology
business.industry
Body Weight
MESH: Time Factors
Interferon-alpha
MESH: Adult
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
Hepatitis C, Chronic
medicine.disease
MESH: Male
Surgery
Discontinuation
MESH: Drug Therapy, Combination
COMBINATION THERAPY
chemistry
MESH: Polyethylene Glycols
3121 General medicine, internal medicine and other clinical medicine
business
TREATMENT DURATION
MESH: Female
Subjects
Details
- ISSN :
- 15273350 and 02709139
- Volume :
- 52
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Hepatology (Baltimore, Md.)
- Accession number :
- edsair.doi.dedup.....122ba338cbf27b99f1ddc6cdb9f46c8e